Literature DB >> 24272200

Decorin-mediated inhibition of cholangiocarcinoma cell growth and migration and promotion of apoptosis are associated with E-cadherin in vitro.

Xiang Yu1, Yanfen Zou, Quan Li, Yonghuan Mao, Hui Zhu, Guangming Huang, Guozhong Ji, Xiagang Luo, Chunzhao Yu, Xiuhua Zhang.   

Abstract

Emerging evidences have shown that decorin expression is significantly reduced in many cancer tissues and cancer cells. However, its biological role and clinical significance in cholangiocarcinoma development and progression are unknown. In this study, immunohistochemistry was conducted to investigate the expression of decorin in cholangiocarcinomas. The results showed that decorin levels markedly decreased in 44 cholangiocarcinoma tissues compared to 40 adjacent normal tissues. The analysis between decorin expression and clinicopathological characteristics in cholangiocarcinoma patients showed that patients with low levels of decorin expression had a relatively poor prognosis. Moreover, recombinant human decorin treatment and overexpression of decorin in cholangiocarcinoma cells could inhibit cell proliferation, migration, and invasion and promote apoptosis. Furthermore, the E-cadherin expression significantly increased after decorin overexpression or use of recombinant human decorin in cholangiocarcinoma cells. Our findings indicated that downregulation of decorin may be identified as a poor prognostic biomarker in cholangiocarcinomas. Also, decorin-mediated inhibition of cholangiocarcinoma cell growth, migration, and invasion and promotion of cell apoptosis might be through regulation of the expression of E-cadherin in vitro.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24272200     DOI: 10.1007/s13277-013-1402-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  34 in total

1.  Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis.

Authors:  Jing-Xu Zhu; Silvia Goldoni; Gregory Bix; Rick T Owens; David J McQuillan; Charles C Reed; Renato V Iozzo
Journal:  J Biol Chem       Date:  2005-07-01       Impact factor: 5.157

2.  De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells.

Authors:  M Santra; T Skorski; B Calabretta; E C Lattime; R V Iozzo
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

3.  Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice.

Authors:  Xiuli Bi; Nicole M Pohl; Zhibin Qian; George R Yang; Yuan Gou; Grace Guzman; Andre Kajdacsy-Balla; Renato V Iozzo; Wancai Yang
Journal:  Carcinogenesis       Date:  2011-12-08       Impact factor: 4.944

4.  Decorin is a biological ligand for the epidermal growth factor receptor.

Authors:  R V Iozzo; D K Moscatello; D J McQuillan; I Eichstetter
Journal:  J Biol Chem       Date:  1999-02-19       Impact factor: 5.157

5.  Changing international trends in mortality rates for liver, biliary and pancreatic tumours.

Authors:  Shahid A Khan; Simon D Taylor-Robinson; Mireille B Toledano; Angus Beck; Paul Elliott; Howard C Thomas
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

Review 6.  Cholangiocarcinoma: lessons from Thailand.

Authors:  Banchob Sripa; Chawalit Pairojkul
Journal:  Curr Opin Gastroenterol       Date:  2008-05       Impact factor: 3.287

7.  Recombinant human decorin upregulates p57KIP² expression in HepG2 hepatoma cell lines.

Authors:  Abdu Selim Hamid; Jinran Li; Yali Wang; Xiaodong Wu; Hassan Abdellah Ahmed Ali; Zhenwu Du; Lihua Bo; Yucheng Zhang; Guizhen Zhang
Journal:  Mol Med Rep       Date:  2013-06-06       Impact factor: 2.952

Review 8.  A review and update on cholangiocarcinoma.

Authors:  Matthew J Olnes; Rodrigo Erlich
Journal:  Oncology       Date:  2004       Impact factor: 2.935

9.  Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation.

Authors:  Xiuli Bi; Chang Tong; Ashley Dockendorff; Laura Bancroft; Lindsay Gallagher; Grace Guzman; Renato V Iozzo; Leonard H Augenlicht; Wancai Yang
Journal:  Carcinogenesis       Date:  2008-06-12       Impact factor: 4.944

10.  Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican.

Authors:  S Chakravarti; T Magnuson; J H Lass; K J Jepsen; C LaMantia; H Carroll
Journal:  J Cell Biol       Date:  1998-06-01       Impact factor: 10.539

View more
  6 in total

Review 1.  Pivotal role for decorin in angiogenesis.

Authors:  Hannu Järveläinen; Annele Sainio; Thomas N Wight
Journal:  Matrix Biol       Date:  2015-02-07       Impact factor: 11.583

2.  Decorin in Human Colon Cancer: Localization In Vivo and Effect on Cancer Cell Behavior In Vitro.

Authors:  Marie C Nyman; Annele O Sainio; Mirka M Pennanen; Riikka J Lund; Sanna Vuorikoski; Jari T T Sundström; Hannu T Järveläinen
Journal:  J Histochem Cytochem       Date:  2015-05-22       Impact factor: 2.479

3.  Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases.

Authors:  Yuefeng Yang; Weidong Xu; Thomas Neill; Zebin Hu; Chi-Hsiung Wang; Xianghui Xiao; Stuart R Stock; Theresa Guise; Chae-Ok Yun; Charles B Brendler; Renato V Iozzo; Prem Seth
Journal:  Hum Gene Ther       Date:  2015-11-10       Impact factor: 5.695

4.  Decorin is responsible for progression of non-small-cell lung cancer by promoting cell proliferation and metastasis.

Authors:  Xuefei Shi; Wenjun Liang; Wen Yang; Rui Xia; Yong Song
Journal:  Tumour Biol       Date:  2014-12-20

5.  Mass spectrometry-based analysis of formalin-fixed, paraffin-embedded distal cholangiocarcinoma identifies stromal thrombospondin-2 as a potential prognostic marker.

Authors:  Johannes Byrling; Theresa Kristl; Dingyuan Hu; Indira Pla; Aniel Sanchez; Agata Sasor; Roland Andersson; György Marko-Varga; Bodil Andersson
Journal:  J Transl Med       Date:  2020-09-04       Impact factor: 5.531

Review 6.  Decorin-mediated oncosuppression - a potential future adjuvant therapy for human epithelial cancers.

Authors:  Annele Orvokki Sainio; Hannu Tapio Järveläinen
Journal:  Br J Pharmacol       Date:  2018-04-02       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.